New insulin set aims to last a full week for type 1 diabetes

NCT ID NCT07325461

Ongoing Disease control Sponsor: Tandem Diabetes Care, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new insulin infusion set designed to last up to 7 days for people with type 1 diabetes. Twenty adults currently using a Tandem insulin pump and Dexcom CGM will try the SteadiSet at home. The goal is to see if the set can survive a full week without causing high blood sugar or other issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SteadiSet Infusion Set (device)
What this could lead to: If successful, this could lead to longer-lasting insulin infusion sets, reducing the need for frequent changes and improving diabetes management.
What could go wrong: This is a small, early feasibility study with only 20 participants. The device may not last the full 7 days for everyone, and results may not apply to all people with type 1 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1

Contacts and locations

Locations

Stanford University

Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.